Preparation and characterization of non-viral gene delivery systems with pEGFP-C1 Plasmid DNA

被引:7
作者
Karagoz, Ugur [1 ]
Kotmakci, Mustafa [1 ]
Akbaba, Hasan [1 ]
Cetintas, Vildan Bozok [2 ]
Kantarci, Gulten [1 ]
机构
[1] Ege Univ, Fac Pharm, Dept Pharmaceut Biotechnol, TR-35100 Izmir, Turkey
[2] Ege Univ, Fac Med, Dept Med Biol, Izmir, Turkey
关键词
Microemulsion; Solid lipid nanoparticle; DNA delivery; Transfection; SOLID LIPID NANOPARTICLES; TOPICAL DELIVERY; MICROEMULSIONS; CYTOTOXICITY; FORMULATION; VECTOR;
D O I
10.1590/s2175-97902018000100265
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In recent years, non-viral delivery systems for plasmid DNA have become particularly important. They can overcome the disadvantages of viral systems such as insertional mutagenesis and unpredicted immunogenicity. Some additional advantages of non-viral gene delivery systems are; good stability, low cost, targetability, delivery of a high amount of genetic materials. The aim of the study was to develop novel non-viral nanosystems suitable for gene delivery. Two formulations were developed for this purpose: water-in-oil microemulsion (ME) and solid lipid nanoparticles (SLN). The microemulsion was composed of Peceol, Tween 80, Plurol oleique, ethanol and water. The SLN was consisting of Precirol, Esterquat-1 (EQ1), Tween 80, Lecithin, ethanol and water. Characterization studies were carried out by measuring particle size, zeta potential, viscosity and pH. TEM imaging was performed on SLN formulations. Protection against DNase I degradation was examined. Cytotoxicity and transfection efficacy of selected formulations were tested on L929 mouse fibroblast cells. Particle sizes of complexes were below 100 nm and with high positive zeta potential. TEM images revealed that SLNs are spherical. The SLN: DNA complexes have low toxicity and good transfection ability. All results showed that the developed SLN formulations can be considered as suitable non-viral gene delivery systems.
引用
收藏
页数:11
相关论文
共 29 条
[1]   Treatment of ocular disorders by gene therapy [J].
Angeles Solinis, M. ;
del Pozo-Rodriguez, Ana ;
Apaolaza, Paola S. ;
Rodriguez-Gascon, Alicia .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2015, 95 :331-342
[2]   Microemulsions for topical delivery of 8-methoxsalen [J].
Baroli, B ;
López-Quintela, MA ;
Delgado-Charro, MB ;
Fadda, AM ;
Blanco-Méndez, J .
JOURNAL OF CONTROLLED RELEASE, 2000, 69 (01) :209-218
[3]   Preparation and characterization of lipid based nanosystems for topical delivery of quercetin [J].
Bose, Sonali ;
Michniak-Kohn, Bozena .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 48 (03) :442-452
[4]   Microemulsion utility in pharmaceuticals: Implications for multi-drug delivery [J].
Callender, Shannon P. ;
Mathews, Jessica A. ;
Kobernyk, Katherine ;
Wettig, Shawn D. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2017, 526 (1-2) :425-442
[5]   DNA delivery via cationic solid lipid nanoparticles (SLNs) [J].
Carrillo, Carolina ;
Sanchez-Hernandez, Noemi ;
Garcia-Montoya, Encarna ;
Perez-Lozano, Pilar ;
Sune-Negre, Josep M. ;
Tico, Josep R. ;
Sune, Carlos ;
Minarro, Montserrat .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 49 (02) :157-165
[6]   Formulation and characterization of food-grade microemulsions as carriers of natural phenolic antioxidants [J].
Chatzidaki, Maria D. ;
Mitsou, Evgenia ;
Yaghmur, Anan ;
Xenakis, Aristotelis ;
Papadimitriou, Vassiliki .
COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS, 2015, 483 :130-136
[7]   Short- and long-term stability study of lyophilized solid lipid nanoparticles for gene therapy [J].
del Pozo-Rodriguez, A. ;
Solinis, M. A. ;
Gascon, A. R. ;
Pedraz, J. L. .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2009, 71 (02) :181-189
[8]   Formulation, characterization and cytotoxicity studies of alendronate sodium-loaded solid lipid nanoparticles [J].
Dolatabadi, Jafar Ezzati Nazhad ;
Hamishehkar, Hamed ;
Eskandani, Morteza ;
Valizadeh, Hadi .
COLLOIDS AND SURFACES B-BIOINTERFACES, 2014, 117 :21-28
[9]   Gene therapy clinical trials worldwide 1989-2004 - an overview [J].
Edelstein, ML ;
Abedi, MR ;
Wixon, J ;
Edelstein, RM .
JOURNAL OF GENE MEDICINE, 2004, 6 (06) :597-602
[10]  
Ege MA., 2004, The 4th pharmaceutics, P36